Drugs / JZP-386
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02215499 | Jul → Nov 2014 | narcolepsy | Concert Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-05-07 | Jazz Pharmaceuticals | Results Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update jazzpharma.com ↗
Clinical data from this Phase 1 study demonstrated that JZP-386 provided favorable deuterium-related effects, including higher serum concentrations and correspondingly increased PD effects at clinically relevant time points compared to Xyrem® (sodium oxybate) oral solution. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-05-07 | Jazz Pharmaceuticals | Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update jazzpharma.com ↗ |
| 2014-12-09 | Jazz Pharmaceuticals | Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update jazzpharma.com ↗ |
| 2014-07-21 | Jazz Pharmaceuticals | Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386 jazzpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JZP-386 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02215499 ↗ |
| Route | Oral | “Oral suspension” NCT02215499 ↗ |